Literature DB >> 11993752

Simulation studies and the alignment of interests.

Godefridus G van Merode1, Siebren Groothuis, Milou Schoenmakers, Hendrikus H Boersma.   

Abstract

Chemotherapy patients are treated with cytostatic drugs. Cytostatic drugs can be produced if ordered or they can be produced to keep in stock. The time that cytostatic drugs can be kept in stock before being spoiled is limited. It is always possible that the patient cannot receive chemotherapy because he/she is not in the right condition. A simulation model is presented which allows to calculate for each combination of patient type and cytostatic drug type the effects on waiting times and costs. In practice actors will behave not as recommended by the simulation model. The cause of the latter is analyzed and solutions are proposed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11993752     DOI: 10.1023/a:1014420730473

Source DB:  PubMed          Journal:  Health Care Manag Sci        ISSN: 1386-9620


  3 in total

1.  Advanced management facilities for clinical laboratories.

Authors:  G G van Merode; A Hasman; J Derks; B Schoenmaker; H M Goldschmidt
Journal:  Comput Methods Programs Biomed       Date:  1996-07       Impact factor: 5.428

2.  Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.

Authors:  D F Bajorin; M F Sarosdy; D G Pfister; M Mazumdar; R J Motzer; H I Scher; N L Geller; W R Fair; H Herr; P Sogani
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

3.  Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.

Authors:  D Bajorin; A Katz; E Chan; N Geller; N Vogelzang; G J Bosl
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

  3 in total
  1 in total

1.  Applying Value Stream Mapping to Improve the Delivery of Patient Care in the Oncology Day Hospital.

Authors:  Pilar I Vidal-Carreras; Julio J Garcia-Sabater; Juan A Marin-Garcia
Journal:  Int J Environ Res Public Health       Date:  2022-04-02       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.